Statement of Ownership (sc 13g)
16 1월 2016 - 4:35AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of
1934
(Amendment No. )*
Vanda Pharmaceuticals Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
921659108
(CUSIP Number)
January 5, 2016
(Date of Event which Requires Filing of
this Statement)
Check the appropriate box to designate the
rule pursuant to which this Schedule is filed:
o |
Rule 13d-1(b) |
|
|
x |
Rule 13d-1(c) |
|
|
o |
Rule 13d-1(d) |
*The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
Persons who respond to the collection of
information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
CUSIP No. 921659108 |
13G |
Page 2 of 9 Pages |
1. |
NAMES OF REPORTING PERSONS
Great Point Partners, LLC
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
37-1475292
|
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) |
o |
(b) |
o
|
3. |
SEC USE ONLY |
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
USA
|
NUMBER OF SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
5. |
SOLE VOTING POWER
0
|
6. |
SHARED VOTING POWER
2,334,119
|
7. |
SOLE DISPOSITIVE POWER
0
|
8. |
SHARED DISPOSITIVE POWER
2,334,119
|
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,334,119
|
10. |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES
(See Instructions)
|
o
|
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.45%1
|
12. |
TYPE OF REPORTING PERSON (See Instructions)
IA
|
|
|
|
|
|
|
| 1 | Based on a total
of 42,815,291 shares outstanding, as reported by the Issuer on a Form 10-Q filed with the SEC on November 4, 2015. |
CUSIP No. 921659108 |
13G |
Page 3 of 9 Pages |
1. |
NAMES OF REPORTING PERSONS |
|
|
|
Dr. Jeffrey R. Jay, M.D. |
|
|
|
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): |
|
|
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
|
(a) |
o |
|
|
|
|
(b) |
o |
|
|
|
3. |
SEC USE ONLY |
|
|
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION |
|
|
|
USA |
|
|
NUMBER OF SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
5. |
SOLE
VOTING POWER |
|
0 |
|
|
6. |
SHARED
VOTING POWER |
|
2,334,119 |
|
|
7. |
SOLE DISPOSITIVE POWER |
|
0 |
|
|
8. |
SHARED
DISPOSITIVE POWER |
|
2,334,119 |
|
|
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON |
|
|
|
|
|
2,334,119 |
|
|
|
|
10. |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES
(See Instructions) |
o |
|
|
|
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
|
|
|
|
|
5.45%1 |
|
|
|
|
12. |
TYPE OF REPORTING PERSON (See Instructions) |
|
|
|
|
|
IN |
|
CUSIP No. 921659108 |
13G |
Page 4 of 9 Pages |
1. |
NAMES OF REPORTING PERSONS |
|
|
|
Mr. David Kroin |
|
|
|
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): |
|
|
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
|
(a) |
o |
|
|
|
|
(b) |
o |
|
|
|
3. |
SEC USE ONLY |
|
|
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION |
|
|
|
USA |
|
|
NUMBER OF SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
5. |
SOLE VOTING POWER |
|
0 |
|
|
6. |
SHARED VOTING POWER |
|
2,334,119 |
|
|
7. |
SOLE DISPOSITIVE POWER |
|
0 |
|
|
8. |
SHARED DISPOSITIVE POWER |
|
2,334,119 |
|
|
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
|
|
|
2,334,119 |
|
|
|
|
10. |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions) |
o |
|
|
|
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
|
|
|
|
|
5.45%1 |
|
|
|
|
12. |
TYPE OF REPORTING PERSON (See Instructions) |
|
|
|
|
|
IN |
|
CUSIP No. 921659108 |
13G |
Page 5 of 9 Pages |
Item 1. |
|
|
|
|
|
|
|
|
(a) |
Name of Issuer
Vanda Pharmaceuticals Inc.
|
|
|
|
|
(b) |
Address of Issuer’s Principal Executive
Offices
2200 Pennsylvania Ave NW, Suite 300E, Washington DC 20037
|
|
|
|
Item 2. |
|
|
|
|
|
|
|
|
(a) |
Name of Person
Filing
Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D.
Mr. David Kroin
|
|
|
|
|
The Reporting Persons have entered into a Joint Filing Agreement,
dated January 15, 2016, a copy of which is filed with this Schedule 13G as Exhibit A, pursuant to which the Reporting Persons
have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act. |
|
|
|
|
(b) |
Address of Principal
Business Office, or if none, Residence
The address of the principal business office of each of the Reporting
Persons is
165 Mason Street, 3rd Floor
Greenwich, CT 06830
|
|
|
|
|
(c) |
Citizenship
|
|
|
|
|
Great Point Partners, LLC is a limited liability company organized
under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. David Kroin is a citizen
of the United States. |
|
|
|
|
(d) |
Title of Class
of Securities
Common Stock
|
|
|
|
|
(e) |
CUSIP Number
921659108
|
|
|
|
Item 3. |
If this statement is filed pursuant to §240.13d-1(b)
or 240.13d.2(b) or (c), check whether the person filing is a:
|
|
|
|
|
Not Applicable. |
|
|
|
(a) |
o |
Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o) |
|
|
|
|
|
(b) |
o |
Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). |
|
|
|
|
|
(c) |
o |
Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C. 78c). |
|
|
|
|
|
(d) |
o |
Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). |
CUSIP No. 921659108 |
13G |
Page 6 of 9 Pages |
|
(e) |
o |
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E). |
|
|
|
|
|
(f) |
o |
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F). |
|
|
|
|
|
(g) |
o |
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G). |
|
|
|
|
|
(h) |
o |
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813). |
|
|
|
|
|
(i) |
o |
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company
Act of 1940 (15 U.S.C. 80a-3). |
|
|
|
|
|
(j) |
o |
Group, in accordance with §240.13d-1(b)(1)(ii)(J). |
Item 4. |
Ownership |
|
|
|
Biomedical Value Fund, L.P. (“BVF”) is the record owner of 746,917 shares (the “BVF Shares”). Great Point Partners, LLC (“Great Point”) is the investment manager of BVF, and by virtue of such status may be deemed to be the beneficial owner of the BVF Shares. Each of Dr. Jeffrey R. Jay, M.D. (“Dr. Jay”), as senior managing member of Great Point, and Mr. David Kroin (“Mr. Kroin”), as special managing member of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares.
Biomedical Institutional Value Fund, L.P. (“BIVF”) is the record owner of 70,024 shares (the “BIVF Shares”). Great Point is the investment manager of BIVF, and by virtue of such status may be deemed to be the beneficial owner of the BIVF Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BIVF Shares, and therefore may be deemed to be the beneficial owner of the BIVF Shares.
Biomedical Offshore Value Fund, Ltd. (“BOVF”) is the record owner of 793,601 shares (the “BOVF Shares”). Great Point is the investment manager of BOVF, and by virtue of such status may be deemed to be the beneficial owner of the BOVF Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares.
|
|
|
|
GEF-SMA, L.P. (“GEF-SMA”) is the record owner of 723,577 shares (the “GEF-SMA Shares”). Great Point is the investment manager with respect to the GEF-SMA Shares, and by virtue of such status may be deemed to be the beneficial owner of the GEF-SMA Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the GEF-SMA Shares, and therefore may be deemed to be the beneficial owner of the GEF-SMA Shares. |
|
|
|
Notwithstanding the above, Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of the BVF Shares, the BIVF Shares, the BOVF Shares and the GEF-SMA Shares, except to the extent of their respective pecuniary interests. |
|
|
|
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. |
|
|
|
|
|
1. |
Great Point Partners, LLC |
|
|
|
|
(a) |
Amount beneficially owned: 2,334,119 |
CUSIP No. 921659108 |
13G |
Page 7 of 9 Pages |
|
(b) |
Percent of class: 5.45%2 |
|
|
|
|
(c) |
Number of shares as to which the person has: |
|
|
|
|
|
(i) |
Sole power to vote or to direct the vote: - 0 - |
|
|
|
|
|
|
(ii) |
Shared power to vote or to direct the vote: 2,334,119 |
|
|
|
|
|
|
(iii) |
Sole power to dispose or to direct the disposition of: - 0 -. |
|
|
|
|
|
|
(iv) |
Shared power to dispose or to direct the disposition of: 2,334,119 |
|
|
|
|
|
2. |
Dr. Jeffrey R. Jay, M.D. |
|
|
|
|
|
(a) |
Amount beneficially owned: 2,334,119 |
|
|
|
|
|
(b) |
Percent of class: 5.45%2 |
|
|
|
|
|
(c) |
Number of shares as to which the person has: |
|
|
|
|
|
|
(i) |
Sole power to vote or to direct the vote: 0. |
|
|
|
|
|
|
(ii) |
Shared power to vote or to direct the vote: 2,334,119 |
|
|
|
|
|
|
(iii) |
Sole power to dispose or to direct the disposition of: 0. |
|
|
|
|
|
|
(iv) |
Shared power to dispose or to direct the disposition of: 2,334,119 |
|
|
|
|
|
3. |
Mr. David Kroin |
|
|
|
|
|
(a) |
Amount beneficially owned: 2,334,119 |
|
|
|
|
|
(b) |
Percent of class: 5.45%2 |
|
|
|
|
|
(c) |
Number of shares as to which the person has: |
|
|
|
|
|
|
(i) |
Sole power to vote or to direct the vote: 0. |
|
|
|
|
|
|
(ii) |
Shared power to vote or to direct the vote: 2,334,119 |
|
|
|
|
|
|
(iii) |
Sole power to dispose or to direct the disposition of: 0. |
|
|
|
|
|
|
(iv) |
Shared power to dispose or to direct the disposition of: 2,334,119 |
Item 5. |
Ownership of Five Percent or Less of a Class |
If this
statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the
beneficial owner of more than five percent of the class of securities, check the following o.
Item 6. |
Ownership of More than Five Percent on Behalf of Another Person: |
|
|
|
See Item 4. |
|
|
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company |
2 |
Based
on a total of 42,815,291 shares outstanding, as reported by the Issuer on a Form 10-Q filed with the SEC on November 4, 2015. |
CUSIP No. 921659108 |
13G |
Page 8 of 9 Pages |
|
Not Applicable. |
|
|
Item 8. |
Identification and Classification of Members of the Group |
|
|
|
Not Applicable. |
|
|
Item 9. |
Notice of Dissolution of Group |
|
|
|
Not Applicable. |
|
|
Item 10. |
Certification |
By signing below I
certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and
are not held in connection with or as participant in any transaction having that purpose or effect.
CUSIP No. 921659108 |
13G |
Page 9 of 9 Pages |
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: January 15,
2016
|
GREAT POINT PARTNERS, LLC |
|
|
|
|
|
|
By: |
/s/ Dr. Jeffrey R. Jay, M.D. |
|
|
|
Dr. Jeffrey R. Jay, M.D., |
|
|
|
as senior managing member |
|
|
|
|
|
|
/s/ Dr. Jeffrey R. Jay, M.D. |
|
|
DR. JEFFREY R. JAY, M.D. |
|
|
|
|
|
|
/s/ Mr. David Kroin |
|
|
MR. DAVID KROIN |
|
Exhibit
A
AGREEMENT REGARDING THE JOINT FILING
OF SCHEDULE 13G
The undersigned hereby agree as follows:
(i) Each of them
is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of
each of them; and
(ii) Each of them
is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of
the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the
information concerning the other persons making the filing, unless such person knows or has reason to believe that such information
is inaccurate.
Date: January 15, 2016
|
GREAT POINT PARTNERS, LLC |
|
|
|
|
|
|
By: |
/s/ Dr. Jeffrey R. Jay, M.D. |
|
|
|
Dr. Jeffrey R. Jay, M.D., |
|
|
|
as senior managing member |
|
|
|
|
|
|
/s/ Dr. Jeffrey R. Jay, M.D. |
|
|
DR. JEFFREY R. JAY, M.D. |
|
|
|
|
|
|
/s/ Mr. David Kroin |
|
|
MR. DAVID KROIN |
|
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024